| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Dechant Robert Thomas | Chief Executive Officer, Director | C/O IBEX LIMITED, 1717 PENNSYLVANIA AVENUE NW, SUITE 825, WASHINGTON | Lisa Lenstrohm, Attorney-in-Fact | 03 Jul 2025 | 0001298255 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | IBEX | Common Shares | Sale | $18,720 | -624 | -0.31% | $30.00 | 198,009 | 02 Jul 2025 | Direct | |
| transaction | IBEX | Common Shares | Sale | $131,280 | -4,376 | -2.2% | $30.00 | 193,633 | 03 Jul 2025 | Direct |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).